



PATENT
674543-2001.4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Walker et al.
Serial No. : 10/081,785
Filed : February 22, 2002
For : REGULATION OF INTRACELLULAR
GLUCOCORTICOID CONCENTRATION
Examiner : Stephen Glucker
Group Art Unit : 1647

JAN 2 2004
TECH CENTER 1600/2900

745 Fifth Avenue, New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 385418080 US

Date of Deposit: May 24, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Charles Jackson
(Typed or printed name of person mailing paper or fee)

Charles Jackson
(Signature of person mailing paper or fee)

TERMINAL DISCLAIMER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the March 9, 2004 Office Action. Enclosed herewith is a check in the amount of \$55.00 in payment of the fee for the filing of a Statutory Disclaimer by a small entity. The Commissioner is hereby authorized to charge any additional fee, or any overpayment in fees, to Deposit Account No. 50-0320.

Claim 14 was rejected under the judicially created doctrine of obviousness-type double patenting as allegedly being unpatentable over claim 1 of U.S. Patent No. 6,368,816 ("the '816 patent"). For the purposes of expediting prosecution, without any admission, without any

05/27/2004 MHEKONEN 00000088 10081785

01 FC:2814

55.00 OP

prejudice, without surrender of subject matter, without any intention of creating any estoppel as to equivalents, a Terminal Disclaimer as to the '816 patent is herewith provided herein:

I, Thomas J. Kowalski, declare that I am the attorney of record and that I am authorized to execute terminal disclaimers on behalf of The University of Edinburgh, the assignee of the above-captioned application ("the present application") and U.S. Patent No. 6,368,816 ("the '816 patent");

That The University of Edinburgh has a place of business at Old College, South Bridge, Edinburgh, EH8 9YL, England;

That The University of Edinburgh is the assignee of the entire right, title and interest in, to and under U.S. Patent application Serial No. 10/081,787, filed February 22, 2002 (the present application) as a divisional of U.S. Application Serial No. 09/029,535, filed February 27, 1998, now U.S. Patent No. 6,368,816 issued on April 9, 2002, by virtue of the assignment from the inventors that was filed with the Patent Office on May 19, 2004 (a copy of which accompanies this Terminal Disclaimer) and which will be recorded at the U.S. Patent and Trademark Office as Reel and Frame to be assigned, on date to be determined;

That The University of Edinburgh is the assignee of the entire right, title and interest in, to and under U.S. Patent No. 6,368,816 (the '816 patent), filed as U.S. Application Serial No. 09/029,535 on February 27, 1998, and issued as U.S. Patent No. 6,368,816 on April 9, 2002, by virtue of the assignment from the inventors that was filed with the Patent Office on May 19, 2004 (a copy of which accompanies this Terminal Disclaimer) and which will be recorded at the U.S. Patent and Trademark Office as Reel and Frame to be assigned, on date to be determined;

That The University of Edinburgh hereby disclaims the terminal part of any patent granted on the present application which would extend beyond the expiration date of the full statutory term of any patent issuing from the '816 patent;

That the Board of Regents hereby agrees that any patent so granted on the present application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the '816 patent, this agreement to run with any patent granted on the present application and to be binding upon the grantee, its successors or assigns;

That no terminal part of any patent granted on the present application is disclaimed prior to the full statutory term of the '816 patent, in the event that the '816 patent earlier expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed

in whole or is terminally disclaimed under 37 C.F.R. §1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term, except for the separation of legal title stated above;

In accordance with 37 C.F.R. § 3.73(b), the undersigned attorney of record, empowered to sign this Statement on behalf of the assignee, states that The University of Edinburgh, is the assignee of the entire right, title and interest in the patent and patent application identified above (the present application and the '816 patent) by virtue of the assignment identified above.

And thus, that the undersigned has reviewed documents in the chain of title of the patent and patent application identified above and, to the best of the undersigned's knowledge and belief, title is in the assignee identified above.

Reconsideration and withdrawal of the double patenting rejection, consideration and entry of this paper and recordal of this Terminal Disclaimer and accompanying Assignment, and reconsideration and withdrawal of the rejection of the Final Office Action, and prompt issuance of a Notice of Allowance, are all respectfully requested; with any fee therefor or any overpayment in such fees, to be charged or credited to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Thomas J. Kowalski by Angela M. Collison
Thomas J. Kowalski
Reg. No. 32,147
Angela M. Collison
Reg. No. 51,107
Tel. (212)588-0800
Fax. (212)588-0500